These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27336860)

  • 1. Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection.
    Emmi G; Silvestri E; Squatrito D; Vitale A; Bacherini D; Vannozzi L; Emmi L; D'Elios MM; Cantarini L; Prisco D
    Int J Dermatol; 2017 Feb; 56(2):218-220. PubMed ID: 27336860
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of anakinra in refractory Behçet's disease sacroiliitis.
    Caso F; Rigante D; Vitale A; Lucherini OM; Cantarini L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S171. PubMed ID: 24709061
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma.
    Orlando I; Vitale A; Rigante D; Lopalco G; Fabiani C; Cantarini L
    Intern Med J; 2017 Sep; 47(9):1086-1088. PubMed ID: 28891187
    [No Abstract]   [Full Text] [Related]  

  • 4. Anakinra for resistant Behçet uveitis: why not?
    Emmi G; Silvestri E; Cameli AM; Bacherini D; Vannozzi L; Squatrito D; Emmi L
    Clin Exp Rheumatol; 2013; 31(3 Suppl 77):152-3. PubMed ID: 24064028
    [No Abstract]   [Full Text] [Related]  

  • 5. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
    Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
    Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH
    Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study.
    Emmi G; Talarico R; Lopalco G; Cimaz R; Cantini F; Viapiana O; Olivieri I; Goldoni M; Vitale A; Silvestri E; Prisco D; Lapadula G; Galeazzi M; Iannone F; Cantarini L
    Clin Rheumatol; 2016 May; 35(5):1281-6. PubMed ID: 26156661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra treatment in drug-resistant Behcet's disease: a case series.
    Cantarini L; Vitale A; Scalini P; Dinarello CA; Rigante D; Franceschini R; Simonini G; Borsari G; Caso F; Lucherini OM; Frediani B; Bertoldi I; Punzi L; Galeazzi M; Cimaz R
    Clin Rheumatol; 2015 Jul; 34(7):1293-301. PubMed ID: 24305945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-1 blockade in neuro-Behçet's disease: a case-based reflection.
    Vitale A; Rigante D; Caso F; Franceschini R; Cantarini L
    Int J Rheum Dis; 2017 Aug; 20(8):1046-1049. PubMed ID: 26032112
    [No Abstract]   [Full Text] [Related]  

  • 10. The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease.
    Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Di Scala G; Sota J; Orlando I; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Ocul Immunol Inflamm; 2020; 28(2):298-304. PubMed ID: 30148652
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN.
    Kotter I; Deuter C; Stubiger N; Zierhut M
    J Rheumatol; 2005 Aug; 32(8):1633; author reply 1634. PubMed ID: 16078350
    [No Abstract]   [Full Text] [Related]  

  • 12. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease.
    Rosenbaum JT
    J Rheumatol; 2004 Jul; 31(7):1241-3. PubMed ID: 15229938
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply: anti-IL1 blocking agents in drug-resistant Behçet's syndrome: our little case series.
    Emmi G; Silvestri E; Ciucciarelli L; Squatrito D; Emmi L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S172. PubMed ID: 24709082
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease.
    Cantarini L; Lopalco G; Caso F; Costa L; Iannone F; Lapadula G; Anelli MG; Franceschini R; Menicacci C; Galeazzi M; Selmi C; Rigante D
    Autoimmun Rev; 2015 Jan; 14(1):1-9. PubMed ID: 25151975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of infliximab on refractory uveitis in Behcet's disease.
    Sayarlioglu M; Cinal A; Topcu N; Demirok A
    Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.
    Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Sota J; Vannozzi L; di Scala G; Guerriero S; Orlando I; Franceschini R; Capozzoli M; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Clin Rheumatol; 2018 Jun; 37(6):1715-1720. PubMed ID: 29671190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis.
    Arayssi T; Hamra R; Homeidan F; Uthman I; Awwad ST; Mroue K; Mansour W; Bashshur ZF
    Clin Exp Rheumatol; 2005; 23(3):427. PubMed ID: 15971438
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term efficacy and safety of Anakinra in a patient with liver transplant due to Adult onset Still's Disease.
    Yilmaz S; Cinar M; Simsek I; Erdem H; Pay S
    Mod Rheumatol; 2014 Nov; 24(6):1030-1. PubMed ID: 24313885
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
    Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
    [No Abstract]   [Full Text] [Related]  

  • 20. Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.
    Fabiani C; Sota J; Vitale A; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Venerito V; Orlando I; Franceschini R; Fusco F; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Ocul Immunol Inflamm; 2019; 27(1):34-39. PubMed ID: 29099660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.